Nine companies in Hangzhou Pharmaceutical Port were selected as "Top 100 Future Medical in the future"

A few days ago, the 6th Future Medical 100 Future Medical 100 of the "Chinese Story" announced the list of "Top 100 Future Medicine in the Future of 2022". Nine companies in Hangzhou Pharmaceutical Port were on the list, showing strong strength.

Founded in 2015, the "Future Medical Top 100" list is one of the most influential industry lists in the domestic medical and health field. The list is mainly aimed at non -listed enterprises. It aims to select Chinese innovative medicalists who truly represent future medical care, discover the core strength of my country's future medical industry, and promote the innovation and change of the health medical industry. Enhe Biology, Suoyuan Biology, first of the biology, the first biology, Jiayin biology, Lingke Pharmaceutical, Belich, and Hodbow, Gebo Biology, and Pao Yuan Pharmaceutical, including Hangzhou Pharmaceutical Port, were on the list.

Hangzhou Pharmaceutical Port, as the only industrial functional area in Zhejiang Province's only 100 billion new industrial platforms, characteristic towns, industrial innovation service complexes, and industrial innovation centers, it has gathered more than 1,500 biomedical companies. From January to May 2022, Hangzhou Pharmaceutical and Pharmaceuticals realized the output value of the biomedical industry of 16.64 billion yuan, an increase of 19.7%year -on -year.

In recent years, Hangzhou Pharmaceutical Port has strengthened cooperation with well -known colleges and universities to build a number of public service platforms such as the Institute of Basic Medicine and Cancer of the Chinese Academy of Sciences, the Biomedical Innovation Public Service Platform of the Biomedical Innovation of the Zhejiang Provincial Pharmaceutical Supervision Bureau, and the Zhejiang University Intelligent Innovation Drug Research Institute; The first -class hospitals in the first -class hospitals of Zhejiang University and the Second Hospital of Zhejiang University have built clinical trial centers to promote innovative drug research and development and results transformation. At the same time, increase support for enterprises, and cooperate with 13 sub -funds in the industrial parent funds and social institutions of Qiantang District. At the same time, the establishment of a direct biomedical investment fund to provide motivation for the subsequent growth of innovation and entrepreneurship projects.

In the next step, Hangzhou Pharmaceutical Port will adhere to the "chain + cluster" development model, continue to play the advantages of the full -chain industrial ecosystem, and effectively play a combination of combinations such as attracting and strong, project construction, ecological optimization, etc. Core competitiveness, make every effort to build the top domestic and world -class biomedical industry innovation highland and manufacturing land. (Reporter Hao Shuang Correspondent Fang Yan)

- END -